MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-GJ-01-0029810
Market Cap
₹3,536 Cr
SHUKRAPHAR · NSE
Share Price
₹79.88
-0.03% today
Revenue
₹56.71 Cr
FY 2025-26 · +74.0% YoY
EBITDA
₹28.78 Cr
Margin 50.8%
Net Profit
₹22.05 Cr
FY 2025-26 · +130.2% YoY
P/E (TTM)
104.0x
P/B 35.0x
ROE
28.9%
ROCE 36.9%
Debt / Equity
0.06
Interest cover 4.5x
About Shukra Pharmaceuticals Limited
Data last updated:
Shukra Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 March 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ1993PLC019079. Its GSTIN is 24AAACR5476N1ZY (Gujarat). The company holds 7 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 524632 and NSE: SHUKRAPHAR.
The company has an authorised share capital of ₹49 Cr and a paid-up capital of ₹43.96 Cr. It was formerly known as Relish Pharmaceuticals Private Limited and Relish Pharmaceuticals Limited. It is led by directors including Dakshesh Rameshchandra Shah (Managing Director) and Shital Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ahmedabad, Gujarat.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹56.71 Cr, a growth of 74% compared to the previous year. For the same year it recorded a net profit of ₹22.05 Cr (net margin 38.9%) and EBITDA of ₹28.78 Cr (EBITDA margin 50.7%). The net worth stands at ₹89.84 Cr (up 43% YoY). Total assets are valued at ₹94.97 Cr (up 41.5% YoY).
The company has about 56 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Shukrapharmaceuticals. As per MCA filings, the company has open charges of ₹14.33 Cr and satisfied charges of ₹21.92 Cr on record. Court records list 50 cases involving the company, including 22 filed by the company and 28 filed against it.
Shukra Pharmaceuticals Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0029810). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website shukrapharmaceuticals.com.
Company details
CIN L24231GJ1993PLC019079
Registration Number 019079
Incorporation Date 04 March 1993
ROC Ahmedabad
Listing Status Listed - Listed on NSE (SHUKRAPHAR); Listed on BSE (524632)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-01-0029810
Name history
Shukra Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Relish Pharmaceuticals Private Limited, and Relish Pharmaceuticals Limited. The current legal name is Shukra Pharmaceuticals Limited.
| Company Name | Status |
|---|---|
| Shukra Pharmaceuticals Limited | Current |
| Relish Pharmaceuticals Private Limited | Previous |
| Relish Pharmaceuticals Limited | Previous |
CIN history
Shukra Pharmaceuticals has one previous CIN (Corporate Identification Number): U24231GJ1993PLC019079. The current CIN is L24231GJ1993PLC019079, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1993PLC019079 | Current |
| U24231GJ1993PLC019079 | Previous |
Key People
Dakshesh Rameshchandra Shah Managing Director Shital Shah Whole-Time Director Anar Jayeshbhai Patel Whole-Time Director Recognitions & Rankings of Shukra Pharmaceuticals
Contact details
Shukra Pharmaceuticals Limited's registered office is in Ahmedabad, Gujarat. Its website is shukrapharmaceuticals.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address3rd Floor Dev House Opp. Wiaa Office Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, India – 380003
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Shukra Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Shukra Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Shukra Pharmaceuticals operates one associated brand: Shukrapharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Affordable generic pharmaceuticals are manufactured and distributed globally. | shukrapharmaceuticals.com |
Business activity
The main business activities of Shukra Pharmaceuticals are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Shukra Pharmaceuticals Limited, buy the company report.
Financials of Shukra Pharmaceuticals Limited
FY 2025-26 filings availableShukra Pharmaceuticals Limited reported revenue of ₹56.71 Cr (up 74% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹56.71 Cr
+74.0% YoY
EBITDA
₹28.78 Cr
+126.3% YoY
Profit After Tax
₹22.05 Cr
+130.2% YoY
Net Worth
₹89.84 Cr
+43.0% YoY
Total Assets
₹94.97 Cr
+41.5% YoY
Total Debt
₹5.02 Cr
+20.1% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 56.71 | 32.59 |
| Revenue growth | +74.0% | - |
| EBITDA | 28.78 | 12.72 |
| EBITDA margin | +50.8% | +39.0% |
| Profit before tax | 28.77 | 13.34 |
| Net profit | 22.05 | 9.58 |
| Net profit margin | +38.9% | +29.4% |
| EPS (₹) | 0.50 | 0.22 |
| Balance sheet | ||
| Total assets | 94.97 | 67.14 |
| Net worth | 89.84 | 62.84 |
| Total debt | 5.02 | 4.18 |
| Cash & bank | 5.92 | 12.12 |
| Net working capital | 62.49 | 49.20 |
| Cash flow | ||
| Cash from operations | 3.15 | 7.92 |
| Cash from investing | (14.18) | (1.26) |
| Cash from financing | 4.83 | (4.52) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.32 | 39.13 | 5.88 | 5.39 | 13.27 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.4% | - | - | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 |
| EBITDA | 18.70 | 19.14 | 0.70 | 27.13 | (0.42) | 1.32 | 7.32 |
| EBITDA margin | +42.3% | +81.4% | +11.1% | +69.3% | -7.1% | +24.5% | +55.2% |
| Depreciation | 1.12 | 1.08 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 |
| Profit before tax | 17.82 | 18.17 | 0.38 | 26.83 | 0.19 | 1.37 | 7.58 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 |
| Net profit | 12.71 | 12.96 | (1.72) | 20.37 | 2.37 | 1.02 | 5.40 |
| EPS (₹) | 0.29 | 0.30 | (0.04) | 0.47 | 0.05 | 0.02 | 0.12 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 56.71 | 32.59 | 74.57 | 58.83 | 20.49 | 11.20 | 11.84 |
| Revenue growth | +74.0% | -56.3% | +26.8% | +187.1% | +83.0% | -5.4% | - |
| EBITDA | 28.73 | 12.72 | 19.40 | 5.35 | 2.89 | 1.24 | 1.52 |
| EBITDA margin | +50.7% | +39.0% | +26.0% | +9.1% | +14.1% | +11.1% | +12.8% |
| Profit before tax | 28.78 | 13.34 | 19.88 | 4.43 | 1.02 | 0.10 | 0.15 |
| Net profit | 22.06 | 9.58 | 18.54 | 4.39 | 0.75 | 0.14 | (0.01) |
| Net profit margin | +38.9% | +29.4% | +24.9% | +7.5% | +3.7% | +1.3% | -0.1% |
| EPS (₹) | 0.50 | 0.22 | 16.93 | 11.26 | 4.79 | 1.20 | 0.23 |
| Balance sheet | |||||||
| Total assets | 94.97 | 67.14 | 60.91 | 30.49 | 19.73 | 25.37 | 23.46 |
| Net worth | 89.84 | 62.84 | 57.64 | 25.29 | 16.35 | 15.60 | 15.42 |
| Total debt | 5.02 | 4.18 | 3.16 | 5.08 | 3.38 | 9.77 | 8.05 |
| Cash & bank | 5.92 | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 |
| Net working capital | 62.49 | 49.20 | 42.56 | 11.89 | 3.74 | 9.02 | 7.48 |
| Cash flow | |||||||
| Cash from operations | 3.15 | 7.92 | (5.20) | 3.17 | 7.99 | 0.54 | 1.24 |
| Cash from investing | (14.18) | (1.26) | (1.20) | (4.43) | (1.53) | (1.89) | (3.36) |
| Cash from financing | 4.83 | (4.52) | 12.41 | 4.94 | (6.68) | 1.74 | 1.99 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.30 | 39.13 | 5.88 | 5.39 | 13.27 | 10.58 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.5% | +269.9% | +5.8% | +69.5% | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 | 1.01 |
| Total expenses | 22.19 | 2.32 | 5.62 | 12.00 | 6.30 | 4.07 | 5.95 | 6.65 |
| EBITDA | 22.01 | 21.20 | 0.68 | 27.13 | (0.42) | 1.32 | 7.32 | 3.93 |
| EBITDA margin | +49.8% | +90.1% | +10.8% | +69.3% | -7.1% | +24.5% | +55.2% | +37.1% |
| Depreciation | 1.12 | 1.07 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 | 0.70 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 | 0.15 |
| Profit before tax | 21.13 | 20.24 | 0.36 | 26.83 | 0.19 | 1.37 | 7.58 | 4.09 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 | 0.93 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.32 | 39.13 | 5.88 | 5.39 | 13.27 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.4% | - | - | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 |
| EBITDA | 18.70 | 19.14 | 0.70 | 27.13 | (0.42) | 1.32 | 7.32 |
| EBITDA margin | +42.3% | +81.4% | +11.1% | +69.3% | -7.1% | +24.5% | +55.2% |
| Depreciation | 1.12 | 1.08 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 |
| Profit before tax | 17.82 | 18.17 | 0.38 | 26.83 | 0.19 | 1.37 | 7.58 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 |
| Net profit | 12.71 | 12.96 | (1.72) | 20.37 | 2.37 | 1.02 | 5.40 |
| EPS (₹) | 0.29 | 0.30 | (0.04) | 0.47 | 0.05 | 0.02 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 56.71 | 32.59 |
| Revenue growth | +74.0% | - |
| Other income | 4.58 | 4.21 |
| Total expenses | 27.93 | 19.87 |
| Employee cost | 6.40 | 5.47 |
| EBITDA | 28.78 | 12.72 |
| EBITDA margin | +50.8% | +39.0% |
| Depreciation | 3.44 | 3.00 |
| Interest | 1.15 | 0.59 |
| Profit before tax | 28.77 | 13.34 |
| Tax | 6.72 | 3.76 |
| Net profit | 22.05 | 9.58 |
| Net profit margin | +38.9% | +29.4% |
| EPS (₹) | 0.50 | 0.22 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 43.79 | 43.79 |
| Reserves & surplus | 40.66 | 19.05 |
| Shareholders' funds (net worth) | 89.84 | 62.84 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 4.33 | 2.70 |
| Unsecured loans | 0.69 | 1.48 |
| Total debt | 5.02 | 4.18 |
| Total liabilities | 94.97 | 67.14 |
| Assets | ||
| Gross block | 49.19 | 43.42 |
| Net block | 21.72 | 19.39 |
| Capital work in progress | 11.91 | 1.95 |
| Investments | 0.03 | 0.00 |
| Inventories | 13.90 | 9.95 |
| Sundry debtors | 22.95 | 8.77 |
| Cash & bank balances | 5.92 | 12.12 |
| Loans & advances | 40.98 | 34.59 |
| Total current assets | 83.75 | 65.43 |
| Total current liabilities | 21.26 | 16.23 |
| Net working capital | 62.49 | 49.20 |
| Total assets | 94.97 | 67.14 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 12.12 | 9.98 |
| Net cash from operating activities | 3.15 | 7.92 |
| Net cash from investing activities | (14.18) | (1.26) |
| Net cash from financing activities | 4.83 | (4.52) |
| Net change in cash | (6.20) | 2.14 |
| Closing cash | 5.92 | 12.12 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +74.0% | - |
| EBITDA growth | +126.3% | - |
| PBT growth | +115.7% | +9997.0% |
| Net income growth | +130.2% | - |
| Profitability & leverage | ||
| Net income margin | +38.9% | +29.4% |
| Return on capital employed | +36.9% | +20.8% |
| Return on net worth | +28.9% | +15.3% |
| Debt / equity | 0.06 | 0.07 |
| Long-term debt / equity | 0.04 | 0.05 |
| Interest cover | 4.54 | 6.07 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.22 | 0.75 |
| Inventory turnover | 4.76 | 3.28 |
| Debtors turnover | 3.58 | 3.72 |
| EPS (₹) | 0.50 | 0.22 |
| Dividend per share (₹) | 0.01 | 0.01 |
| Book value per share (₹) | 1.93 | 1.44 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.30 | 39.13 | 5.88 | 5.39 | 13.27 | 10.58 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.5% | +269.9% | +5.8% | +69.5% | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 | 1.01 |
| Total expenses | 22.19 | 2.32 | 5.62 | 12.00 | 6.30 | 4.07 | 5.95 | 6.65 |
| EBITDA | 22.01 | 21.20 | 0.68 | 27.13 | (0.42) | 1.32 | 7.32 | 3.93 |
| EBITDA margin | +49.8% | +90.1% | +10.8% | +69.3% | -7.1% | +24.5% | +55.2% | +37.1% |
| Depreciation | 1.12 | 1.07 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 | 0.70 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 | 0.15 |
| Profit before tax | 21.13 | 20.24 | 0.36 | 26.83 | 0.19 | 1.37 | 7.58 | 4.09 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 | 0.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 56.71 | 32.59 | 74.57 | 58.83 | 20.49 | 11.20 | 11.84 |
| Revenue growth | +74.0% | -56.3% | +26.8% | +187.1% | +83.0% | -5.4% | - |
| Other income | 4.58 | 4.21 | 2.82 | 1.20 | 0.08 | 0.36 | 0.11 |
| Total expenses | 27.98 | 19.87 | 55.17 | 53.48 | 17.60 | 9.96 | 10.32 |
| Employee cost | 0.00 | 5.47 | 5.02 | 4.41 | 4.57 | 3.75 | 4.34 |
| EBITDA | 28.73 | 12.72 | 19.40 | 5.35 | 2.89 | 1.24 | 1.52 |
| EBITDA margin | +50.7% | +39.0% | +26.0% | +9.1% | +14.1% | +11.1% | +12.8% |
| Depreciation | 3.44 | 3.00 | 2.05 | 1.84 | 1.66 | 1.47 | 1.48 |
| Interest | 1.09 | 0.59 | 0.29 | 0.28 | 0.29 | 0.03 | 0.00 |
| Profit before tax | 28.78 | 13.34 | 19.88 | 4.43 | 1.02 | 0.10 | 0.15 |
| Tax | 6.72 | 3.76 | 1.34 | 0.04 | 0.27 | (0.09) | 0.14 |
| Net profit | 22.06 | 9.58 | 18.54 | 4.39 | 0.75 | 0.14 | (0.01) |
| Net profit margin | +38.9% | +29.4% | +24.9% | +7.5% | +3.7% | +1.3% | -0.1% |
| EPS (₹) | 0.50 | 0.22 | 16.93 | 11.26 | 4.79 | 1.20 | 0.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 43.79 | 43.79 | 10.95 | 3.91 | 1.57 | 1.57 | 1.57 |
| Reserves & surplus | 40.66 | 19.05 | 46.69 | 21.38 | 14.78 | 14.03 | 13.85 |
| Shareholders' funds (net worth) | 89.84 | 62.84 | 57.64 | 25.29 | 16.35 | 15.60 | 15.42 |
| Secured loans | 4.33 | 2.70 | 1.75 | 2.21 | 1.10 | 0.66 | 0.00 |
| Unsecured loans | 0.69 | 1.48 | 1.41 | 2.87 | 2.28 | 9.11 | 8.05 |
| Total debt | 5.02 | 4.18 | 3.16 | 5.08 | 3.38 | 9.77 | 8.05 |
| Total liabilities | 94.97 | 67.14 | 60.91 | 30.49 | 19.73 | 25.37 | 23.46 |
| Assets | |||||||
| Gross block | 49.19 | 43.42 | 40.97 | 39.57 | 35.07 | 33.53 | 31.74 |
| Net block | 21.72 | 19.39 | 19.95 | 20.24 | 17.58 | 17.70 | 17.38 |
| Capital work in progress | 11.91 | 1.95 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 |
| Investments | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.05 |
| Inventories | 13.90 | 9.95 | 2.31 | 3.16 | 3.95 | 1.68 | 1.39 |
| Sundry debtors | 22.95 | 8.77 | 24.51 | 30.19 | 7.40 | 9.75 | 7.95 |
| Cash & bank balances | 5.92 | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 |
| Loans & advances | 40.98 | 34.59 | 19.42 | 15.76 | 4.23 | 4.13 | 4.99 |
| Total current assets | 83.75 | 65.43 | 56.22 | 53.08 | 15.87 | 16.06 | 14.46 |
| Total current liabilities | 21.26 | 16.23 | 13.66 | 41.19 | 12.13 | 7.04 | 6.98 |
| Net working capital | 62.49 | 49.20 | 42.56 | 11.89 | 3.74 | 9.02 | 7.48 |
| Total assets | 94.97 | 67.14 | 60.91 | 30.49 | 19.73 | 25.37 | 23.46 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 | 0.25 |
| Net cash from operating activities | 3.15 | 7.92 | (5.20) | 3.17 | 7.99 | 0.54 | 1.24 |
| Net cash from investing activities | (14.18) | (1.26) | (1.20) | (4.43) | (1.53) | (1.89) | (3.36) |
| Net cash from financing activities | 4.83 | (4.52) | 12.41 | 4.94 | (6.68) | 1.74 | 1.99 |
| Net change in cash | (6.20) | 2.14 | 6.01 | 3.68 | (0.21) | 0.38 | (0.12) |
| Closing cash | 5.92 | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +74.0% | -56.3% | +26.8% | +187.1% | +83.0% | -5.4% | - |
| EBITDA growth | +125.9% | -34.4% | +262.6% | +85.1% | +133.1% | -18.4% | - |
| PBT growth | +115.7% | -32.9% | +348.8% | +334.3% | +920.0% | -33.3% | -79.5% |
| Net income growth | +130.3% | -48.3% | +322.3% | +485.3% | +435.7% | +1500.0% | - |
| Revenue CAGR (3Y) | -1.2% | +16.7% | +88.1% | +70.6% | +53.6% | +27.8% | +32.1% |
| EBITDA CAGR (3Y) | +75.2% | +63.9% | +150.1% | +52.1% | +20.5% | -8.2% | +1.4% |
| Profitability & leverage | |||||||
| Net income margin | +38.9% | +29.4% | +24.9% | +7.5% | +3.7% | +1.7% | +0.1% |
| Return on capital employed | +36.9% | +21.8% | +44.2% | +18.8% | +5.8% | +1.4% | +0.4% |
| Return on net worth | +28.9% | +15.9% | +44.7% | +21.2% | +4.7% | +0.9% | +0.1% |
| Debt / equity | 0.06 | 0.06 | 0.10 | 0.20 | 0.41 | 0.57 | 0.46 |
| Long-term debt / equity | 0.04 | 0.05 | 0.08 | 0.17 | 0.40 | 0.57 | 0.46 |
| Interest cover | 4.54 | 6.07 | 1.67 | 7.98 | 23.58 | -13.04 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.22 | 0.77 | 1.85 | 1.58 | 0.60 | 0.34 | 0.46 |
| Inventory turnover | 4.76 | 5.32 | 27.27 | 16.55 | 7.28 | 7.30 | 16.54 |
| Debtors turnover | 3.58 | 1.96 | 2.73 | 3.13 | 2.39 | 1.27 | 2.06 |
| EPS (₹) | 0.50 | 0.22 | 16.93 | 11.26 | 4.79 | 1.20 | 0.23 |
| Dividend per share (₹) | 0.01 | 0.01 | 1.00 | 0.50 | 0.50 | 0.00 | 0.00 |
| Book value per share (₹) | 1.93 | 1.44 | 52.65 | 64.63 | 104.43 | 99.63 | 98.43 |
To see the full year-wise statements and ratios of Shukra Pharmaceuticals Limited, buy the company report.
Board of directors of Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals has 12 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Payal Sujay Mehta Also directs: Parshva Next Innovations Limited | Director | 23 May 2012 | 14 Years 5 Months | Current |
| Dakshesh Rameshchandra Shah | Managing Director | 26 May 2012 | 14 Years 5 Months | Current |
| Dinesh Chauhan Also directs: Craftroot Retail Limited | Additional Director | 30 Dec 2025 | 0 Years 10 Months | Current |
| Shital Shah Also directs: Esperic Solution LLP, Parshva Texchem (India) Private Limited, Seher Retail Private Limited and 5 more | Whole-Time Director | 25 Oct 2024 | 2 Years 0 Months | Current |
| Ritu Kapoor Also directs: Craftroot Retail Limited, Shukra AI Private Limited, Kapoor and Raval Trdewing LLP and 3 more | Director | 25 Oct 2024 | 2 Years 0 Months | Current |
| Anar Jayeshbhai Patel Also directs: Armieda Makeover Private Limited, Craftroot Retail Limited, Anar Project Private Limited and 5 more | Whole-Time Director | 10 Jul 2024 | 2 Years 3 Months | Current |
Showing 6 of 12 current directors. View all directors
Peer comparison
Shukra Pharmaceuticals Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Shukra Pharmaceuticals Limitedthis company | ₹56.71 Cr (FY 2026) | ₹22.05 Cr | 38.9% | 74.0% | 56 | Ahmedabad, Gujarat, India |
| Nexus Pharma Chem Private Limited | ₹37.01 Cr (FY 2025) | 17.0% | Ahmedabad, Gujarat, India | |||
| Lexine Technochem Private Limited | ₹36.97 Cr (FY 2025) | 22.0% | Salvli, Gujarat, India | |||
| Mednext Biotech Limited | ₹36.86 Cr (FY 2025) | -32.0% | Udaipur, Rajasthan, India | |||
| Bharat Explosives Limited | ₹36.81 Cr (FY 2025) | -13.0% | Uttar Pradesh, India | |||
| Gitanjali Chemicals Private Limited | ₹36.72 Cr (FY 2024) | -21.0% | Mumbai, Maharashtra, India | |||
| Anphar Organics Private Limited. | ₹36.7 Cr (FY 2025) | 17.0% | Jammu, Jammu and Kashmir, India | |||
| Balaji Formulations Private Limited | ₹36.59 Cr (FY 2023) | -10.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Shukra Pharmaceuticals Limited, buy the company report.
Auditor
Shukra Pharmaceuticals Limited is audited by MAAK and Associates for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MAAK and Associates | FY 2025 | 135024W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 51.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 48.90%.
Sep 2026
QUARTER
51.00% Promoters
0.10% DII (Domestic Institutional)
48.90% Retail & Others
Promoter holding - history
Now 51.00% · Sep 2026High 51.00% · Dec 2025Low 51.00% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 51.00% | 51.00% | 51.00% | 51.00% |
| Public | 49.00% | 49.00% | 49.00% | 49.00% |
Charges & borrowings
Open charges
₹14.33 Cr
Satisfied charges
₹21.92 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Apr 2026 | 101287091 | Others | ₹9.9 Cr | Open | |
| 11 Mar 2026 | 101268496 | Others | ₹1.6 Cr | Open | |
| 24 Aug 2025 | 101144979 | Others | ₹28.89 Lakh | Open | |
| 06 Aug 2025 | 101144794 | Others | ₹28.8 Lakh | Open | |
| 16 Dec 2022 | 100661995 | Tata Capital Financial Services Limited | ₹75 Lakh | Open |
To see the full charge records of Shukra Pharmaceuticals Limited, buy the company report.
Total charge records: 19 View all charges
Legal cases
Shukra Pharmaceuticals Limited has 50 court cases on record: 22 filed by Shukra Pharmaceuticals, 28 filed against it. All cases are disposed.
Total cases
50
Filed by the company
22
Filed against the company
28
Disposed
50
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 27 | 10 | 0 |
| District courts | 22 | 17 | 0 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 50)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Madras High Court | Writ petition | Filed against the company by Immersivevision Technology Private Limited, | Disposed |
| Madras High Court | Interim or miscellaneous application | Filed against the company by Immersivevision Technology Private Limited, | Disposed |
| High Court, GUJARAT | Special civil application | Filed by the company against , Ahmedabad and 1 other | Disposed |
| District court, Ahmedabad, Gujarat | Court case (SMST R) | Filed against the company by Pci Pest Control Pvt Ltd | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (S S) | Filed against the company by Ms Novartis India Ltd. | Disposed |
To see the full case history of Shukra Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Shukra Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Shukra Pharmaceuticals Limited has a workforce of 56 employees on its EPFO records as of Jan 24, 2026, across 1 active EPFO establishment.
Employee count
56
Active EPFO establishments
1
Employee growth
-43.43%
GST
Shukra Pharmaceuticals has 7 GST registrations: 7 active. The first 4 active GSTINs are listed below.
Total GSTINs
7
Active
7
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACR5476N1ZY | Gujarat | Active | 01 Jul 2017 |
| 24AAACR5476N2ZX | Gujarat | Active | 21 Feb 2018 |
| 24AAACR5476N3ZW | Gujarat | Active | 09 May 2025 |
| 27AAACR5476N1ZS | Maharashtra | Active | 18 Mar 2025 |
To see the full GST registrations and return filing status of Shukra Pharmaceuticals Limited, buy the company report.
Recent activity
Shukra Pharmaceuticals Limited has 48 board changes on record since 1993: 30 appointments and 18 cessations. The latest: Bhoomiben Patel ceased to be Director on 30 Dec 2025.
Charges
A charge registered on 06 Sep 2024 via Charge ID 100970269 with Others was fully satisfied on 26 Jun 2026.
Charges
A charge with Others amounted to Rs. 9.90 Cr with Charge ID 101287091 was registered on 17 Apr 2026.
Filing
Shukra Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 1.60 Cr with Charge ID 101268496 was registered on 11 Mar 2026.
Ceased
Bhoomiben Patel ceased to be Director.
Appointed
Dinesh Chauhan was appointed as Additional Director.
AGM
Shukra Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 0.29 Cr with Charge ID 101144979 was registered on 24 Aug 2025.
Charges
A charge with Others amounted to Rs. 0.29 Cr with Charge ID 101144794 was registered on 06 Aug 2025.
Appointed
Ritu Kapoor was appointed as Director.
Appointed
Shital Shah was appointed as Whole-Time Director.
Charges
A charge with Others of Rs. 6.00 Cr registered on 06 Sep 2024 with Charge ID 100970269 was modified on 13 Sep 2024.
80 earlier events are in the company report.
News
Frequently asked questions
Shukra Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 March 1993 (33+ years old) and is registered under CIN L24231GJ1993PLC019079. Listed on BSE: 524632 and NSE: SHUKRAPHAR.
Shukra Pharmaceuticals reported revenue of ₹56.71 Cr for FY 2025-26 (up 74% YoY) based on consolidated financials.
Shukra Pharmaceuticals has 12 current directors:
- Dakshesh Rameshchandra Shah - Managing Director
- Shital Shah - Whole-Time Director
- Anar Jayeshbhai Patel - Whole-Time Director
- Sanskruti Jayeshbhai Patel - Whole-Time Director
- Dhruvin Shah - Whole-Time Director
- Payal Sujay Mehta - Director
- Dinesh Chauhan - Additional Director
- Ritu Kapoor - Director
- Jitendra Somchand Shah - Director
- Pinki Nirmal Sagar - Director
- Sonal Deepalbhai Gandhi - Director
- Sarjeevan Singh - Director
The latest financial statements of Shukra Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Shukra Pharmaceuticals is 24AAACR5476N1ZY, registered in Gujarat. The company has 7 GST registrations in all, of which 7 are active. Other active GSTINs include 24AAACR5476N2ZX (Gujarat), 24AAACR5476N3ZW (Gujarat), 27AAACR5476N1ZS (Maharashtra).
The CIN (Corporate Identification Number) of Shukra Pharmaceuticals is L24231GJ1993PLC019079. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Shukra Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 524632) and NSE (symbol: SHUKRAPHAR).
Shukra Pharmaceuticals has 50 court cases on record: 22 filed by the company and 28 filed against it. Most are in the high courts.
Shukra Pharmaceuticals was incorporated on 04 March 1993, making it 33+ years old. It is registered with the Registrar of Companies, Ahmedabad.
The peers of Shukra Pharmaceuticals by revenue are Nexus Pharma Chem Private Limited, Lexine Technochem Private Limited, Mednext Biotech Limited, Bharat Explosives Limited, Gitanjali Chemicals Private Limited and 2 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Bhoomiben Patel ceased to be Director on 30 Dec 2025. Dinesh Chauhan was appointed as Additional Director on 30 Dec 2025. Ritu Kapoor was appointed as Director on 25 Oct 2024. Shukra Pharmaceuticals has 48 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages